#PU

sustainhealth.fit

The Third Chapter Can Be Your Best One Yet

Midlife achievement can lose its shine. Discover why identity, purpose and participation may offer a healthier way to approach ageing.

pubmed.ncbi.nlm.nih.gov

Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

CONCLUSIONS: A substantial treatment gap exists in the use of CGRP mAbs among eligible individuals with migraine in Japan. Improving access to specialist care, enhancing patient-physician communication, and increasing awareness of preventive treatment options are critical to a...

pubmed.ncbi.nlm.nih.gov

Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study

CONCLUSIONS: A substantial treatment gap exists in the use of CGRP mAbs among eligible individuals with migraine in Japan. Improving access to specialist care, enhancing patient-physician communication, and increasing awareness of preventive treatment options are critical to a...

pubmed.ncbi.nlm.nih.gov

Integrated Multi-Omics Analyses Identify Acupuncture-Associated Changes in Gut Microbiota, Short-Chain Fatty Acids, and TNC Gene Expression in Chronic Migraine Rats

CONCLUSION: In NTG-induced CM rats, TA reduced hyperalgesia and neuroinflammation, accompanied by changes in gut microbiota, SCFA profiles, and TNC gene expression, providing preliminary associative evidence that warrants further mechanistic and clinical validation.

le-sages.org

pubmed.ncbi.nlm.nih.gov

Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study

CONCLUSION: Erenumab 70 mg showed a consistent and well-tolerated safety profile observed over a longer treatment duration along with sustained clinical benefit. No new safety signals were observed versus DBTP and prior global phase 3 studies.